Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901033 | 0.90 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL1388845 | 0.90 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL8222998 | 0.87 | SLC10A2 (0.69) | SLC10A2 | |
| SCHEMBL7465895 | 0.87 | SLC10A2 (0.69) | SLC10A2 | |
| SCHEMBL7465899 | 0.87 | SLC10A2 (0.69) | SLC10A2 | |
| SCHEMBL7475921 | 0.85 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL7475916 | 0.85 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL1361732 | 0.85 | SLC10A2 (0.79) | SLC10A2 | |
| SCHEMBL9961479 | 0.85 | SLC10A2 (0.81) | SLC10A2 | |
| SCHEMBL8216485 | 0.85 | SLC10A2 (0.85) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | disclosed |
| EP-1427713-B1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ALBIREO AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-7125864-B2 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | ALBIREO AB (SE) | 2006-05-04 | — | — | US | disclosed |
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ALBIREO AB (SE) | 2005-02-10 | — | — | US | disclosed |
| EP-1427713-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | Astrazeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022825-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885 |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.